Bris­tol-My­ers in­vites J&J in­to an al­liance of gi­ants on car­dio drug de­vel­op­ment/com­mer­cial­iza­tion pro­gram

8 years ago
R&D
Pharma

#AACR18: Roche spot­lights promis­ing sub­group re­spons­es for lung can­cer com­bo with Tecen­triq

8 years ago
R&D

Genen­tech inks $359M deal with Kine­ta; Celldex bat­tered af­ter ADC flops in PhI­Ib

8 years ago
News Briefing

Who won big at #AACR18? Mer­ck surges on Keytru­da/chemo com­bo while Bris­tol-My­ers shares tum­ble on com­par­i­son

8 years ago
R&D

#AACR: Mer­ck spot­lights piv­otal Keytru­da/chemo da­ta, hop­ing to break down skep­ti­cism to its front­line lung can­cer duo

8 years ago
R&D

#AACR: Bris­tol-My­ers tunes out sta­t­ic, broad­casts im­pres­sive re­sults for Op­di­vo/Yer­voy lung can­cer com­bo

8 years ago
R&D

End­points' Chi­na cov­er­age is get­ting deep­er. An­nounc­ing our part­ner­ship with Pharm­Cube, the lead­ing Chi­nese bio­phar­ma ...

8 years ago
Publisher's note
China

Servi­er buys Shire's on­col­o­gy unit for $2.4B in the run-up to Takeda's fi­nal buy­out of­fer — if it makes one

8 years ago
Pharma

In a stun­ning about face, the FDA is now wel­com­ing the new drug ap­pli­ca­tion from Alk­er­mes it re­ject­ed 2 weeks ago

8 years ago
Pharma

#AACR18 round 1: Mer­ck takes a di­rect swing at Bris­tol-My­ers with ad­ju­vant melanoma da­ta for Keytru­da

8 years ago
R&D

Flag­ship’s Evelo Bio­sciences pitch­es $100M IPO for a new plat­form of mon­o­clon­al mi­cro­bials

8 years ago
Financing

Al­ny­lam flags loom­ing FDA ap­pli­ca­tion for givosir­an, adding an­oth­er round of stel­lar ef­fi­ca­cy da­ta from ear­ly study

8 years ago
R&D

Dal­cor taps new CEO Fouzia Laghris­si-Th­ode as piv­otal PhI­II looms; Kel­ly Mar­tin set­tles in at No­van; Ed­ward Stew­art ...

8 years ago
Peer Review

Ad­ynxx drug failed in PhII but it’s go­ing in­to PhI­II any­way; Deer­field leads $50M raise for Sol­lis

8 years ago
News Briefing

In­ven­ti­va rais­es $44M as it preps for a PhI­II NASH pro­gram, up­com­ing IIb read­out

8 years ago
Financing

Af­ter pa­tient deaths, failed part­ner­ships and a stock scan­dal, Han­mi fi­nal­ly gives up on con­tro­ver­sial ol­mu­tinib. ...

8 years ago
R&D

Penn team spot­lights a pi­lot ovar­i­an can­cer tri­al and sur­vival rates for a per­son­al­ized can­cer vac­cine

8 years ago
R&D
Discovery

Re­tire? Bill Chin’s tried it three times, and he’d rather be work­ing at Fre­quen­cy Ther­a­peu­tics

8 years ago
People
Peer Review

Next-gen­er­a­tion se­quenc­ing: FDA of­fers guid­ance to stream­line path to mar­ket

8 years ago
Pharma

As gene edit­ing ex­plodes, a new re­port from Gold­man says Chi­nese groups are seiz­ing the lead on CRISPR and CAR-T ...

8 years ago
China

Pfiz­er launch­es a gene ther­a­py study for Duchenne MD; Am­gen, NEA back re­al-world drug da­ta soft­ware com­pa­ny

8 years ago
News Briefing

FDA launch­es crim­i­nal probe in­to unau­tho­rized her­pes vac­cine R&D backed by Pe­ter Thiel

8 years ago
People

Does the FDA’s ‘break­through’ drug pro­gram need to be re­formed? Har­vard skep­tics say yes

8 years ago
Bioregnum
Pharma

For­mer No­vo chair­man Göran An­do joins the board as Tes­sa bags $50M in ad­di­tion­al fund­ing

8 years ago
Financing
First page Previous page 1051105210531054105510561057 Next page Last page
A service from the Financial Times